Fresenius SE & Co. KGaA (FRE) AI Stock Analysis

• Market Cap: €28.89B
• Dividend Yield: 2.05%
• Average Volume (3M): 750.62K
• Price to Earnings (P/E): 25.5
• Beta (1Y): 0.65
• Revenue Growth: 0.63%
• EPS Growth: N/A
• Country: DE
• Employees: 175,202
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 563,237,300
• 10 Day Avg. Volume: 787,875
• 30 Day Avg. Volume: 750,621
• PEG Ratio: -0.22
• Price to Book (P/B): 0.97
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 12.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €54.84
• Price Target Upside: 9.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: €51.00 ▲(1.96% Upside)
• Action: Reiterated Date: 12/18/25
• Date: Action: Reiterated 12/18/25

Fresenius SE & Co. KGaA's overall score is driven by strong financial performance, particularly in revenue growth and profitability. However, technical indicators show mixed signals, and valuation metrics suggest the stock is fairly valued. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates a robust demand for its healthcare products and services, supporting long-term business expansion and market presence.

Market Position

Fresenius's leading position in the dialysis market provides a competitive edge, ensuring steady revenue streams and reinforcing its market dominance.

Profitability

Sustained profitability margins reflect efficient cost management and pricing power, supporting long-term financial health and shareholder value.

Negative Factors

Cash Flow Conversion

The decline in free cash flow growth could limit the company's ability to fund new investments or return capital to shareholders, impacting long-term growth potential.

Operational Efficiency

Opportunities for enhancing operational efficiency could impact profitability if not addressed, potentially affecting competitive positioning and cost structure.

Shareholder Returns

The modest return on equity indicates that there is room to enhance shareholder returns, which could be a focus area for management to improve investor confidence.

Fresenius SE & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

How the Company Makes Money

Fresenius generates revenue through multiple key segments. Fresenius Medical Care is the largest revenue contributor, driven by the sale of dialysis machines, dialyzers, and related services, providing treatment to patients with chronic kidney failure. Fresenius Kabi earns revenue from intravenous (IV) solutions, infusions, and nutrition products, catering to hospitals and healthcare providers. Fresenius Helios operates a network of private hospitals in Germany, earning revenue through patient care services and hospital stays. Additionally, Fresenius Vamed generates income through healthcare facility management and development projects. The company also engages in strategic partnerships and collaborations in the healthcare sector, which enhance its market reach and product offerings, further contributing to its earnings.

Fresenius SE & Co. KGaA Financial Statement Overview

Summary

Fresenius SE & Co. KGaA demonstrates strong revenue growth and profitability with a solid income statement. The balance sheet is stable with manageable leverage, but cash flow conversion needs improvement.

Income Statement

Fresenius SE & Co. KGaA shows a solid income statement performance with a consistent revenue growth trajectory, as evidenced by a 53.5% revenue growth in the TTM period. The company maintains a healthy gross profit margin of 25.4% and a net profit margin of 5.1% in the TTM, indicating strong profitability. However, the EBIT and EBITDA margins, while improving, suggest room for operational efficiency improvements.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.70 in the TTM, indicating a balanced leverage position. Return on equity is at 5.9%, showing profitability but with potential for improvement. The equity ratio stands at 43.9%, suggesting a stable financial structure, though the company should focus on enhancing shareholder returns.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth, with a negative growth rate of -2.18% in the TTM. The operating cash flow to net income ratio is 1.91, indicating strong cash generation relative to net income. However, the free cash flow to net income ratio of 0.56 suggests potential challenges in converting earnings into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.35B	21.83B	22.30B	40.84B	37.52B	36.28B
Gross Profit	5.58B	5.38B	5.06B	10.72B	10.31B	10.32B
EBITDA	3.34B	2.95B	2.73B	3.09B	6.84B	7.19B
Net Income	1.14B	471.00M	-594.00M	1.37B	1.82B	1.71B
Balance Sheet
Total Assets	42.46B	43.55B	45.28B	76.42B	71.96B	66.65B
Cash, Cash Equivalents and Short-Term Investments	2.36B	2.05B	2.56B	2.35B	2.75B	2.00B
Total Debt	13.54B	13.58B	15.83B	27.76B	27.16B	25.91B
Total Liabilities	23.19B	23.26B	25.63B	44.20B	42.67B	40.62B
Stockholders Equity	18.62B	19.54B	19.00B	20.41B	19.00B	16.95B
Cash Flow
Free Cash Flow	1.21B	1.52B	3.32B	2.28B	3.03B	4.14B
Operating Cash Flow	2.19B	2.45B	4.46B	4.20B	5.08B	6.55B
Investing Cash Flow	-725.00M	-510.00M	-3.19B	-2.61B	-2.82B	-3.01B
Financing Cash Flow	-560.00M	-2.18B	-1.38B	-1.60B	-1.45B	-3.12B

Fresenius SE & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FRE, the sentiment is Positive. The current price of 50.02 is above the 20-day moving average (MA) of 49.92, above the 50-day MA of 49.22, and above the 200-day MA of 46.34, indicating a bullish trend. The MACD of 0.87 indicates Negative momentum. The RSI at 62.73 is Neutral, neither overbought nor oversold. The STOCH value of 71.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FRE.

Fresenius SE & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	76 Outperform	€55.89B	18.91	10.32%	1.82%	1.47%	9.64%
FME	64 Neutral	€11.74B	16.47	5.41%	3.54%	2.10%	9.19%
FRE	62 Neutral	€28.89B	25.53	7.50%	2.05%	0.63%	―
SHL	58 Neutral	€46.31B	21.94	11.45%	2.13%	4.53%	10.12%
BAYN	54 Neutral	€45.00B	-226.18	-0.66%	0.31%	-1.87%	77.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRT	48 Neutral	€14.61B	84.69	5.01%	0.39%	5.82%	59.90%